Fewer Than 3% of Early Alzheimer’s Patients Are Hitting All 15 Brain-Health Goals
Fewer than 3 people out of every 100 with early Alzheimer’s disease are meeting all 15 brain-health recommendations their doctors say they should follow – and that figure holds even among patients who agreed to receive an anti-amyloid infusion drug every two weeks, undergo monitoring for serious side effects, and attend repeat clinical appointments. Researchers at the Mass General Brigham Neuroscience Institute assumed this group, given the demands they had already accepted, would show stronger adherence to everyday brain-protective habits. They did not.
Both patients with early Alzheimer’s who pursued treatment with lecanemab and patients who did not pursue anti-amyloid therapy showed poor adherence to brain health recommendations, with no significant difference between the groups. The researchers studied 150 patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who were seeking anti-amyloid antibody therapy, and compared them with 117 patients who were not pursuing the therapy. Mild cognitive impairment, or MCI, is the stage at which memory and thinking problems are worse than normal aging but have not yet disrupted everyday functioning – and the stage at which patients are still capable of actively participating in decisions about their own care.
What the Brain Health Vital Signs Tool Actually Measures for Alzheimer’s Brain Health
The study, published in The Journal of Prevention of Alzheimer’s Disease, used a purpose-built assessment called Brain Health Vital Signs. The tool examines 15 areas of potentially modifiable health, and fewer than 3% of the patients studied followed all 15 recommendations.
Those 15 areas cover a wide range: physical activity, diet, sleep quality, stress levels, blood pressure control, blood sugar management, body weight, cognitive engagement, social connection, hearing health, vision, smoking, alcohol use, medication adherence, and mental health. The goal is to give clinicians a structured map showing which areas are already solid and which need attention.
Among patients pursuing anti-amyloid therapy, more than 25% were not optimally adhering to 11 of the 15 brain health recommendations, and more than 50% were not optimally adhering to four of the recommendations. Physical activity was the single biggest gap. The recommendation calls for at least 25 minutes of movement on most days of the week, and 63% of the lecanemab-seeking group didn’t reach it.
Why Exercise Matters So Much for Alzheimer’s Brain Health
That exercise gap carries real consequences. An analysis of multiple studies found that regular physical activity reduces Alzheimer’s disease risk by 45%. Physical activity increases blood flow to the brain, supports the growth of new neurons, and reduces inflammation. It also maintains the health of blood vessels, which are among the most important structural supports for a functioning brain as people age.
Patients who cannot reach 25 minutes of movement most days are missing one of the most studied protective factors in the Alzheimer’s literature – not a wellness recommendation, but a modifiable risk factor with substantial evidence behind it.
Sleep, Stress, and the Hidden Barriers
Sleep is another category where reality consistently falls short of recommendation. During deep sleep, cerebrospinal fluid circulates through the brain to clear neurotoxic proteins and plaques, including beta-amyloid – the same protein that lecanemab targets pharmacologically. Patients relying on medication to reduce amyloid while sleeping poorly are working against themselves.
Sleep disturbances are common in mild cognitive impairment and are bidirectionally linked to cognitive decline – the disease disrupts sleep, and poor sleep accelerates cognitive decline. That circular dynamic makes it one of the harder targets to address without structured clinical support.
Stress management is another area where adherence is difficult. Chronic psychological stress is linked to accelerated cognitive deterioration, and research published in Aging and Mental Health found that highly stressed older adults are twice as likely to develop mild cognitive impairment. For patients already navigating an Alzheimer’s diagnosis, preparing for demanding treatment schedules, and managing caregiver relationships, reducing stress without practical tools and support is genuinely difficult.
Blood Pressure, Hearing, and the Overlooked Risk Factors
Hypertension is an independent modifiable risk factor for dementia, and blood pressure control is among the most evidence-supported targets for reducing cognitive decline. Blood sugar management and body weight – both captured in the Brain Health Vital Signs assessment – work alongside blood pressure control to reduce vascular contributors to cognitive deterioration.
Hearing loss is one of the factors most consistently underestimated in conversations about Alzheimer’s brain health. It is identified as one of the largest modifiable risk factors for cognitive impairment and dementia. The risk compounds when both hearing and vision are affected: people with both vision and hearing problems are more likely to experience cognitive decline and develop dementia than those with neither impairment, according to Alzheimer’s Research UK. Patients who have not had hearing or vision checked recently have a meaningful, actionable reason to do so.
Memory problems themselves make it harder to remember routines, organize exercise, prepare healthy food, and take medications correctly. The disease that creates the need for better health habits also undermines the cognitive capacity required to build and maintain them. A patient can understand that a 30-minute walk would help and still be unable to consistently organize, initiate, or remember to take one.
Practical barriers compound this: fatigue, depression, limited finances, transportation difficulties, physical limitations, and the weight of caregiver demands all reduce the likelihood that advice alone translates into behavior change. Telling a patient that exercise is beneficial is not the same as helping them become active.
What This Means for You
An anti-amyloid drug targets the protein deposits in the brain. Regular movement, good sleep, controlled blood pressure, treated hearing loss, and managed stress target the conditions that allow those deposits to cause damage. The two approaches address different parts of the same problem, and most patients are currently receiving only one of them in any structured way.
For anyone with a family member in early Alzheimer’s or MCI, a practical step following a diagnosis is to ask the treating neurologist directly about Brain Health Vital Signs or a comparable structured assessment – which of the 15 modifiable factors are already well-managed, and which are not. Ask whether the clinic offers coaching, referral, or follow-up support for specific categories such as exercise or sleep. Social connection and cognitive engagement, areas linked to lower dementia risk, are worth prioritizing – they are also among the areas where families can directly help. The U.S. POINTER trial demonstrated that structured programs combining exercise, nutrition, cognitive engagement, and health monitoring improved cognition in older adults at risk of cognitive decline.
Meanwhile, the treatment landscape is shifting. In July 2026, the FDA approved a subcutaneous, at-home formulation of lecanemab – the first time patients can begin treatment through home administration by themselves or their caregiver. The approved initiation regimen is 500 mg given once weekly as two 250 mg injections. Removing the clinic visit burden from treatment initiation could free up both patient energy and clinical bandwidth for addressing lifestyle factors, but only if the health system treats both as equally important.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
